TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00207233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT oil hypocaloric liquid diet
Description: The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LCT hypocaloric liquid diet
Description: The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous abdominal adipose tissue biopsy
Description: Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous abdominal adipose tissue biopsy
Description: Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks.
Study: NCT03206476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the SCT and the TM
Description: Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional information
Description: Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
Study: NCT04335747

Intervention type: OTHER
Intervention: COVID-19 infection
Description: Hospitalisation due to a confirmed COVID-19 infection

Intervention type: OTHER
Intervention: COVID-19 infection
Description: Hospitalisation due to a confirmed COVID-19 infection
Study: NCT02895334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHeartBaby Program
Description: Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
Study: NCT03104777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviourally Informed Intervention Materials
Description: The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress.
Study: NCT05773027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE
Description: SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Control Condition
Description: The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
Study: NCT03652584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Study: NCT02600767

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
Study: NCT03774134

Intervention type: PROCEDURE
Intervention: Complete mesocolic excision
Description: Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.

Intervention type: PROCEDURE
Intervention: Conventional colon resection
Description: The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
Study: NCT02214862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F18]-FDDNP
Description: radiopharmaceutical tracer
Study: NCT00623051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Male Circumcision
Study: NCT03906851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity and diet
Description: Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
Study: NCT03059251

Intervention type: BIOLOGICAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
Study: NCT01164917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG811
Description: Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG811 Placebo
Description: 8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
Study: NCT04066777

Intervention type: PROCEDURE
Group type: OTHER
Intervention: alcohol septal ablation
Description: injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
Study: NCT02721303

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-day diet Run-in
Description: Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-day diet Run-in
Description: Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-day diet Run-in
Description: Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
Study: NCT02264964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath®
Description: Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation
Description: 500 patients will undergo AVF creation in either arm for femoral vein catheterization group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath®
Description: Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation
Description: 900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
Study: NCT01470664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100
Description: 0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100 (Component #1)
Description: 0.6% PVP-Iodine ophthalmic solution alone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FST-100 Vehicle
Description: FST-100 Vehicle
Study: NCT03703349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo for Magnesium
Study: NCT03179774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Description: All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Description: All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
Study: NCT02428816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI acquisition
Description: MRI acquisitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI acquisition
Description: MRI acquisitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI acquisition
Description: MRI acquisitions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral evaluations
Description: Evaluations about motor abilities, sleep, cognition and lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral evaluations
Description: Evaluations about motor abilities, sleep, cognition and lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral evaluations
Description: Evaluations about motor abilities, sleep, cognition and lifestyle
Study: NCT02690493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Taping
Description: Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Functional Taping
Description: Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
Study: NCT02721303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous catheter placed for blood draws
Description: On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
Study: NCT00523549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 160 mg or 320 mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 160 mg or 320 mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: 5 mg or 10 mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: 5 mg or 10 mg tablets once a day
Study: NCT03463577

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
Study: NCT02721303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous catheter placed for blood draws
Description: On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous catheter placed for blood draws
Description: On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
Study: NCT01550107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300mg b.d for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablets
Description: matched placebo tablets b.d
Study: NCT03463577

Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
Study: NCT03987490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Vaccine reminder notification sent via text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Vaccine reminder notification sent via text
Study: NCT02952872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Tablet-based Intervention to Address Heavy Alcohol Use
Description: The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Tablet-based Intervention to Address Heavy Alcohol Use
Description: The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
Study: NCT03864666

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100 mg
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
Study: NCT03987490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PostCard
Description: Vaccine reminder notification sent via standard mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: No additional information given to parents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: No additional information given to parents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
Study: NCT04493697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental 1
Description: A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental 2
Description: A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
Study: NCT06380647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acyclovir
Description: Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Acyclovir
Description: Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
Study: NCT00292981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
Study: NCT02153190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYBRID
Description: During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYBRID
Description: During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPEN
Description: During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPEN
Description: During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
Study: NCT05470959

Intervention type: OTHER
Group type: OTHER
Intervention: ACTIVA bioactive
Description: bioactive ionic resin composite

Intervention type: OTHER
Group type: OTHER
Intervention: Riva LC
Description: resin-modified glass ionomer